Product Images Sildenafil Citrate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Sildenafil Citrate NDC 0904-6671 by Major Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

0de47bba 965a 4039 9237 f10ea6d9f669 00

0de47bba 965a 4039 9237 f10ea6d9f669 00

This is a product description of sildenafil tablets, USP. The tablets come in blister packs of 4 and each tablet contains 1020mg of sildenafil. There is advice to consult a healthcare professional regarding proper usage and safety precautions. There are also instructions to keep the medication out of reach of children and to store it in a tightly sealed container with acid-resistant material. The description also includes a prescription warning and pharmacy information.*

2 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 01

2 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 01

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 02

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 02

7 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 03

7 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 03

This is a table that shows the drug fold change and corresponding 90% confidence interval (CI) recommendation for interacting drugs with Atorvastatin, Adithromycin, Bosentan, Cimetidine, Mes, Erythromycin, Maslox, Oral Contraceptives, Rioravir, and Saquinavir in terms of AUC and cmax. The study found that adding Sildenafil to Bosentan therapy did not improve exercise capacity based on clinical studies.*

8 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 04

8 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 04

This text appears to be a table that lists different drugs and their potential interactions with the drug Acenocoumarol. The table provides information on the impact of the interaction on INR AUC, Cmax, and fold change with an 80% Cl. Based on the effects, there are recommendations for dose adjustment and co-administration. Some drugs require no dose adjustment and are safe to co-administer, while others are not recommended or require further monitoring. The table also includes some clinical study results on exercise capacity when Sidonati is added to Bosentan therapy.*

4 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 05

4 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 05

5 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 06

5 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 06

This is a clinical trial data that includes the dosage of Placebo and Sildenafil 20 mg TID administered to a group of patients diagnosed with Idiopathic PAH. The data includes the mean PAP, gender, age, and walk distance and its change in 6-minutes before and after administering the medication.*

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 07

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 07

Figure 12 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 08

Figure 12 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 08

The given text is a figure showing the mean change from baseline in the six-minute walk test in meters for a study involving the use of Sildenafil. The data is presented for the ITT population up to week 12. The figure shows a line graph with three treatment groups: Sildenafil 1mg TID, Sildenafil 5mg TID, and Sildenafil 20mg TID. The X-axis shows the weeks of the study, and the Y-axis shows the change from baseline (meters). The figure includes error bars, representing Standard Error, and provides information on the mean change in each treatment at each visit.*

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 09

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 09

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 10

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 10

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.